Key result
Updated guidelines no longer recommend starting beta-blocker therapy on the day of noncardiac surgery due to emerging evidence of increased risks for bradycardia, stroke, and death.
Why the study?
Evidence-based recommendations for perioperative beta-blocker use in noncardiac surgery shifted from strong advocacy to cautious use, necessitating a review of the mechanisms and evidence behind this change.
Does perioperative beta-blocker therapy reduce major adverse cardiac events in patients undergoing noncardiac surgery?
Does perioperative beta-blocker therapy reduce major adverse cardiac events in patients undergoing noncardiac surgery?
This review highlights the paradigm shift in perioperative beta-blocker guidelines, emphasizing the risks of stroke and mortality when initiating therapy immediately before noncardiac surgery.
Supports guideline caution on same-day beta-blocker use; leaves open timing questions for future studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Toshiharu Azma (2020) conducted a review in Patients undergoing noncardiac surgery. Perioperative beta-blocker therapy was evaluated. Updated guidelines no longer recommend starting beta-blocker therapy on the day of noncardiac surgery due to emerging evidence of increased risks for bradycardia, stroke, and death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: